# Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

> **NCT05509530** · PHASE2 · UNKNOWN · sponsor: **Xuzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** anti-BCMA/GPRC5D CAR-T CELL

## Key facts

- **NCT ID:** NCT05509530
- **Lead sponsor:** Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509530, "Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05509530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*